Highlight Therapeutics
Madrid, Spain· Est.
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Private Company
Total funding raised: $33.4M
About
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
BiologicsRNA & Gene Therapy
Funding History
2Total raised:$33.4M
Series B$23.4M
Series A$10M